Nephro Care India Limited (NSE: NEPHROCARE) is a Kolkata, West Bengal-based company in the Hospitals and Healthcare Centers industry. With a market capitalisation of ₹130 Cr, it ranks #3,020 by market cap among the 6,197 Indian listed companies on FinBizNet, and #30 of 46 in Hospitals and Healthcare Centers. At ₹81.40 (as of 16 Nov 2026), the share price is 47.9% below its 52-week high of ₹156.35 and 62.6% above its 52-week low of ₹50.05. The share price is down 27.5% over one year and up 1.4% over three months.
| Current Price | ₹81.40 |
|---|---|
| Market Cap | ₹130 Cr |
| NSE Symbol | NEPHROCARE |
| Sector | Health Care > Health Care Equipment and Services > Health Care Providers and Services |
| Sub-Industry | Health Care Facilities > Hospitals and Healthcare Centers |
| P/E Ratio | 39.9 |
| Return on Equity | 5.93% |
| Return on Assets | 3.74% |
| 52-Week Range | ₹50.05 – ₹156.35 |
| 1-Year Price Change | -27.5% |
| 3-Month Price Change | +1.4% |
| Beta (1Y) | 1.24 |
| Headquarters | Kolkata, West Bengal |
| Website | www.nephrocareindia.com |
| Revenue | ₹29 Cr |
|---|---|
| Net Profit | ₹2 Cr |
| Net Margin | 5.5% |
| EPS (Basic) | ₹0.98 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Promoters held 61.71% of Nephro Care India Limited's shares as of Jun 2026, against 61.38% in Dec 2024 (+0.33 percentage points).
Nephro Care India Limited, provides treatment for kidney-related diseases in India. The company offers care for renal failure patients that include consultation, treatment, and yoga; nutritional support, including nutritional support for weight loss/weight gain, body composition analysis, anthropometry, and lifestyle education and support services for diabetic kidney disease, hypertensive nephropathy, glomerular disease, renal transplant recipient, hemodialysis patient, IgA nephropathy, lupus nephropathy, and ADPKD; and lifestyle and rehabilitation programs. Its clinics provides renal transplant, urology, vascular surgery, carepath diagnostics, digital radiology, cardiology, OT facilities, women welfare services. In addition, the company offers pulmonary function test, EMG/NCV-testing, uroflowmetry, EEG, polysomnography, and retinal screening services. The company was incorporated in 2014 and is based in Kolkata, India.
1. Ipd Services-This segment provides in-patient department services. 2. Opd Services-This segment provides out-patient department services. 3. Sale of Medicines From Pharmacy-This segment engages in the sale of medicines from pharmacy. 4. Inter-segment Sales-NA
1. Healthcare Facilities & Services-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Apollo Hospitals Enterprise Limited | ₹1,23,712 Cr | 63 | 21.50% | ₹7,615 Cr | +11.6% |
| Max Healthcare Institute Ltd | ₹91,978 Cr | 63.9 | 14.33% | ₹2,569 Cr | -16.6% |
| Manipal Health Enterprises Ltd | ₹89,110 Cr | 88.4 | — | ₹3,399 Cr | — |
| Aster Dm Healthcare Limited (Asterdm) | ₹63,041 Cr | 97.6 | 10.07% | ₹2,829 Cr | +4.3% |
| Fortis Healthcare Ltd. | ₹58,283 Cr | 55.1 | 11.01% | ₹2,735 Cr | -25.1% |
| Global Health Ltd (Medanta) | ₹38,422 Cr | 69.7 | 15.03% | ₹1,469 Cr | +16.2% |
| Narayana Hrudayalaya Limited | ₹37,907 Cr | 46.2 | 19.85% | ₹2,844 Cr | +2.8% |
| Krishna Institute Of Medical Science (KIMS) | ₹29,056 Cr | 120.6 | 9.72% | ₹1,344 Cr | +0.2% |
| Nephro Care India Limited | ₹130 Cr | 39.9 | 5.93% | ₹29 Cr | -27.5% |
Listed by market capitalisation. Ratios are shown for context only.
Nephro Care India Limited is trading at ₹81.40, with a market capitalisation of ₹130 Cr.
Nephro Care India Limited operates in the Health Care > Health Care Equipment and Services > Health Care Providers and Services space (Health Care Facilities > Hospitals and Healthcare Centers).
Nephro Care India Limited has a P/E of 39.9 and a return on equity of 5.93%.
Nephro Care India Limited is listed on the NSE under the symbol NEPHROCARE.
Nephro Care India Limited's share price is down 27.5% over one year and up 1.4% over three months. Its 52-week range is ₹50.05 to ₹156.35.
In Q1 FY27, Nephro Care India Limited reported revenue of ₹29 Cr and net profit of ₹2 Cr, with basic EPS of ₹0.98 (consolidated, parsed from the company's exchange filing).
Promoters held 61.71% of Nephro Care India Limited's shares as of Jun 2026, against 61.38% in Dec 2024 (+0.33 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.